is an economic
consulting company that utilises leading
edge tools and approaches to assist investors,
researches and policy makers in a range of bio-science fields
FOPH note the aim of the HTA is to evaluate the effectiveness, safety, costs, cost-effectiveness and budget impact of CGRP antagonists compared to standard of care medications in patients who suffer from episodic and/or chronic migraine.
